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INTRODUCTION
Asthma is a chronic inflammatory disorder of airway with
long history, even described by Hippocrates (1, 2). Tradition-
ally, asthma has been regarded as a clinical manifestation of
allergic response to environmental agents (1). However, avail-
able epidemiological evidences suggest that the portion of
asthma cases attributable to allergic sensitization (atopy) is
less than one half (3). This indicates that the importance of
etiological mechanism other than allergic mechanism might
be neglected (3). This is especially true when considering the
patients with severe asthma are more frequently nonallergic
compared to those with mild-to-moderate asthma (4). The
nonallergic asthma has been suggested as an autoimmune
disease on the basis of frequent detection of circulating autoan-
tibodies in patients with nonallergic asthma (1, 5-7). How-
ever, a causal relationship between autoimmunity and asthma
has not been demonstrated mainly due to lack of identifica-
tion of pathogenetically and logically relevant autoantigen (8).
On a pathological viewpoint, airway epithelium has been
suggested as a major target tissue for inflammatory response
in asthma regardless of allergic sensitization (9) and could be
a potential target of autoimmune response in asthma (10). We
previously identified the cytokeratin 18 (CK18) protein as
an airway epithelial autoantigen associated with nonallergic
asthma while exploring the hypothesis that an autoimmune
response to airway epithelial cell proteins might be involved
in the pathogenesis of asthma (10).
Apoptosis and loss of adhesion of bronchial epithelial cells
have been reported in patients with asthma and these have
attributed to secretion of TNF-alpha and interferon gamma
by T cells and eosinophils (11). Caspase-3 is a key mediator
of apoptosis in mammalian cells and cleavage of CK18 pro-
tein by caspase-3 is a marker of early apoptosis in epithelial
cells (12, 13). It has been reported that the apoptotic caspase-
3 protein was increased in bronchial epithelial cells of asth-
matic patients, when compared with healthy controls (14).
In this study, the bindings of IgG autoantibodies to the
fragments of CK18 protein cleaved by caspase-3 were analy-
zed by Western blot to investigate the antigen-binding cha-
racteristics of IgG autoantibodies in nonallergic asthma.
MATERIALS AND METHODS
Subjects
We used serum samples from three patients with nonaller-
gic asthma who had circulating IgG autoantibodies against
CK18 protein (Table 1). All patients had typical clinical his-
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Antigen-binding Characteristics of Circulating IgG Autoantibodies to
Cytokeratin 18 Protein in Patients with Nonallergic Asthma
Cytokeratin 18 (CK18) protein was identified as an airway epithelial cell autoantigen
associated with nonallergic asthma. Cleavage of CK18 protein by caspase-3 is a
marker of early apoptosis in epithelial cells. It has been shown that the expression
of active caspase-3 was increased in bronchial epithelial cells of asthmatic patients,
when compared with healthy controls. To investigate the antigen-binding charac-
teristics of IgG autoantibodies to CK18 protein in nonallergic asthma, the bindings
of IgG autoantibodies to the fragments of CK18 protein cleaved by caspase-3 were
analyzed by Western blot using serum samples from three patients with nonallergic
asthma. Recombinant human CK18 protein was treated by caspase-3 and cleaved
into N-terminal fragment (1-397 amino acids) and C-terminal fragment (398-430
amino acids). The binding capacity of IgG autoantibodies to N-terminal fragment
of CK18 was maintained in one patient and reduced in other two patients. IgG auto-
antibodies from all three patients did not bind to C-terminal fragment of CK 18. In
conclusion, IgG autoantibodies to CK18 protein from patients with nonallergic asth-
ma seems to preferentially bind to the whole molecule of CK18 protein and their
antigen-binding characteristics were heterogeneous among the patients with non-
allergic asthma. 
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tory of asthma and documented reversibility of FEV1 greater
than 15% after inhalation of bronchodilator. All patients un-
derwent skin-prick test with 50 common aeroallergens (Ben-
card Co., Brentford, U.K.). Nonallergic asthma was defined
when there was no positive skin reaction to any of the 50 com-
mon aeroallergens in the presence of a positive histamine con-
trol. All serum samples from subjects were aliquoted and
stored at -20℃. All subjects gave informed consent, and the
institutional review board approved this study. 
Western blot analysis of IgG autoantibodies to CK18 protein
Recombinant human CK18 protein (Research Diagnostics
Inc., Pleasant Hill Road Flanders, NJ, U.S.A.) was separated
by discontinuous sodium dodecyl sulphate/polyacrylamide
gel electrophoresis (SDS-PAGE) using an 8% resolving gel
(pH 8.8) and a 4% stacking gel (pH 6.8). Following electro-
phoresis, proteins were transferred onto a polyvinylidine difluo-
ride membrane (Bio-Rad Laboratories, Hercules, CA, U.S.A.).
After the transfer, the membrane strips were probed with 1
mL of serum samples at dilution of 1 in 100 (v/v) for 2 hr at
room temperature. After washes, the membrane was incu-
bated with alkaline phosphatase-conjugated goat anti-human
IgG (Sigma Chemical Co., St. Louis, MO, U.S.A.) for 2 hr
at room temperature. After a final washing, the membrane
was stained with a substrate solution (nitro blue tetrazolium/
5-bromo-4-chloro-3-indoyl phosphate; Sigma Chemical Co.).
A mouse monoclonal antibody to human CK18 protein (clone
no. CY-90, Sigma Chemical Co.) known to recognize a epi-
tope located in the region of 312-356 amino acids of CK18
was used as a positive control (15). Alkaline phosphatase-con-
jugated goat anti-mouse IgG (Sigma Chemical Co.) was used
for detection of mouse monoclonal antibody.
In vitro cleavage of CK18 protein by caspase-3
1  g of recombinant human cytokeratin 18 protein was
incubated with 1  g of caspase-3 (BD Biosciences, San Diego,
CA, U.S.A.) in a 40  L volume containing 50 mM HEPES,
0.1 M NaCl, 10% sucrose, 0.1% CHAPS, and 10 mM DTT
for 4 hr at 37℃and the reaction was stopped by adding SDS-
PAGE sample buffer as described in a previous report (16).
RESULTS
Site-specific cleavage of CK18 protein by caspase-3
Caspase 3 has been reported to cleave 
394DALD/S site of
CK18 protein (16) (Fig. 1). We observed degradation of 49-
kDa recombinant human cytokeratin 18 protein into 45-kDa
fragment (corresponding N-terminal 1-397 amino acids; visi-
ble in Fig. 2) and 4-kDa fragment (corresponding C-terminal
398-430 amino acids; invisible in protein staining due to small
molecular weight of this fragment in Fig. 2). 
Binding of circulating IgG autoantibodies to fragments of
CK18 produced by caspase-3
The binding capacity of IgG autoantibodies to N-terminal
fragment (1-397 amino acid) of CK18 was maintained in one
Patients 1 2 3
Sex Male Female Female
Age (yr) 40 66 66
Duration of asthma (yr) 8 9 17
Baseline FEV1 (L) 3.43 1.58 1.11
(% predicted) (74.5) (78.0) (46.7)
Atopy on skin prick test Negative Negative Negative
Total IgE (IU/mL) 195 716 195
Peripheral blood eosinophils (/ L) 700 200 2,200
Table 1. Clinical characteristics of three patients with nonallergic
asthma
Fig. 1. Cleavage of cytokeratin 18 protein by caspase-3 at the se-
quence 
394DALD/S (arrow). Cleavage of 49-kDa cytokeratin 18 pro-
tein (A) by caspase-3 results in 45-kDa fragment (B) and 4-kDa
fragment (C).
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Fig. 2. Protein stain of cytokeratin 18, caspase-3, and fragments
of cytokeratin 18 treated by caspase-3. 0.25  g of caspase-3 only
(lane 1), 0.25  g of cytokeratin 18 treated by 0.05  g of caspase-
3 (lane 2), molecular weight marker (lane 3), 0.25  g of cytokeratin
18 only (lane 4), and 0.25  g of cytokeratin 18 treated by 0.25  g
of caspase-3 (lane 5).
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patient and reduced in other two patients (Fig. 3). IgG auto-
antibodies from all three patients did not show significant
binding to C-terminal fragment (398-430 amino acids) of
CK18 (Table 2). Mouse monoclonal IgG antibody to CK18
(clone CY-90; Sigma Chemical Co.) bound to the N-terminal
fragment (1-397 amino acids) with same intensity of binding
to whole molecule of CK18 protein (Fig. 3).
DISCUSSION
The presence of circulating IgG autoantibodies to CK18
could be just a reflection of epithelial damage in patients with
nonallergic asthma considering recent evidence that the bron-
chial epithelium is more susceptible to injury in this group
(17). Or the IgG autoantibodies could be a pathogenic factor
contributing the development of chronic airway inflamma-
tion in nonallergic asthma. 
Apoptosis is a biochemically and morphologically distinct
form of programmed cell death, initiated by specific signals
that activate specific caspases (13). As a result, the cell is elimi-
nated by an intrinsic suicide program, resulting in DNA frag-
mentation, nuclear condensation, cytoskeletal reorganization,
plasma membrane blebbing, and loss of cell adhesion (13).
Apoptosis and loss of adhesion of bronchial epithelial cells
have been reported in asthma and these have attributed to
secretion of TNF-alpha and interferon gamma by T cells and
eosinophils in asthmatic airway mucosa (11). Caspase inhi-
bitor was shown to decrease airway inflammation in mouse
model of asthma (18). Inhibition of epithelial cell apoptosis
by corticosteroids has been suggested to be a mechanism of
anti-asthmatic property of corticosteroids (19). Cleavage of
CK18 protein by caspases and the exposure of specific CK18
neo-epitope identifiable by monoclonal antibody M30 (the
same CK18 epitope exposed by caspase-3 in this study) has
been reported to be a specific feature of early apoptosis (13).
In previous study on idiopathic pulmonary fibrosis, the devel-
opment of circulating IgG antibodies to cytokeratin 18 pro-
tein was suggested to be an secondary immune response to
neo-epitopes of CK18 exposed by caspases during the apop-
tosis (20). In this study, we showed that IgG autoantibodies
to cytokeratin 18 from patients with nonallergic asthma pref-
erentially bound with whole molecule of CK18 protein, rather
than the apoptotic fragments cleaved by caspase-3 and their
antigen-binding characteristics were heterogeneous among
the patients with nonallergic asthma. There is a certain limi-
tation on the interpretation of these results due to the small
number of patients (only three patients) because relatively
large volumes of serum samples were needed for multiple re-
peated experiments. However, results of this study suggest
that the autoantibody response to CK18 in nonallergic asthma
might not be a secondary phenomenon associated with apop-
totic death of airway epithelial cells due to chronic airway
inflammation.
The idea of a possible involvement of autoimmunity in the
pathogenesis of asthma has been proposed by earlier studies
which demonstrated higher incidences of various autoanti-
bodies against antigens in bronchial mucosa, paranasal sinus,
lung, and endothelial cell in asthmatic patients compared to
healthy controls (5-7). Analysis of T cell in airway fluid from
patients with non-atopic asthma showed features of clonal ex-
pansion indicating the antigen-induced activation of T cells
in the airway of non-atopic asthma (21). A significant corre-
lation between T cell proliferative response to the 55-kDa
endothelial autoantigen and the degree of airway obstruction
has been reported in asthmatic patients (7). Patients with se-
vere asthma can be clinically improved by anti-CD4 antibody
treatment (22). In mouse model, non-atopic airway hyperre-
sponsiveness could be passively transferred by CD4+ T cells
(23). In rat model of autoimmune emphysema, transfer of
pathogenic CD4+ T cells or antibodies developed by immu-
nizing endothelial cell proteins caused emphysema (24). These
-, no biniding; ±, very weak binding; +, weak binding; ++, moderate
binding; +++, strong binding. 
Binding intensity
Patients
CK18 whole
molecule 
(amino acid
1-430)
CK18 frag-
ment 
(amino acid
1-397)
CK18 frag-
ment 
(amino acid
398-430)
1 +++ + -
2+ ++ + -
3 +++ ± -
Table 2. Binding of IgG autoantibodies in serum samples from
nonallergic asthma to fragments of cytokeratin 18 (CK18) treat-
ed by caspase-3
Fig. 3. Binding of IgG autoantibodies from three patients with non-
allergic asthma to the fragments of cytokeratin 18 protein treated
by caspase-3. Lane 1, 3, 5, and 7: 0.2  g of cytokeratin 18 protein
not treated by caspase. Lane 2, 4, 6, and 8: 0.2  g of cytokeratin
18 protein treated by 0.2  g of caspase-3. mAb: mouse monoclon-
al antibody to human cytokeratin 18 (clone no. CY-90, Sigma Co.,
St. Louis, MO, U.S.A.) known to recognize an epitope located in
the region of 312-356 amino acids of cytokeratin 18 protein. 
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suggest that a T cell response to an ‘as-yet unidentified auto-
antigen’ could be involved in the pathogenesis of nonallergic
asthma (1, 25). However, further studies including the T cell
response to autoantigens and development of animal model
for autoimmune asthma are necessary to determine the patho-
genetic significance of autoimmunity in nonallergic asthma.
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